Skip to content

Research & Culture5 min readBy Lola · Updated November 11, 2026

Oregon and Colorado: What Legal Psilocybin Programmes Have Shown So Far

Oregon and Colorado: What Legal Psilocybin Programmes Have Shown So Far

For decades, almost everything known about psilocybin in people came from small, tightly controlled clinical trials. That changed when two American states opened supervised programmes for adults. Oregon has offered psilocybin services since 2023, and Colorado's first healing centres were licensed in 2025.

These programmes are not clinical trials. Nobody needs a diagnosis or a prescription, and there is no placebo group. But they produce something trials cannot: real-world data on thousands of ordinary adults. Here is what the official figures and the first published studies have reported so far.

This is general information, not medical advice.

How Oregon's programme works

Oregon voters approved Measure 109 in 2020. The Oregon Health Authority issued the first psilocybin service centre licence in May 2023, to EPIC Healing Eugene, which began seeing clients the following month.

The model is built around supervision rather than therapy.

  • Clients must be 21 or older and do not need a referral from a doctor.
  • Everyone first completes a preparation session with a licensed facilitator.
  • Psilocybin is taken at a licensed service centre, with a facilitator present for the whole session.
  • Products are grown, tested and sold within a licensed system, so each session uses a measured amount of psilocybin.

Since 2025, a state law has required service centres to report anonymous data, which the health authority publishes on a public dashboard.

Oregon's first full year of data

The 2025 figures are the clearest picture yet of who uses a legal psilocybin service.

  • The Oregon Health Authority reported 5,935 clients in 2025, and 18,868 psilocybin products sold within the regulated system.
  • The authority recorded 13 contacts with emergency services that year, which it reported as 0.2 per cent of clients.

In 2026, Yu and colleagues analysed the same dashboard data in a paper published in Frontiers in Psychiatry. They counted 5,375 sessions, most of them individual and 747 in groups. Clients peaked in the second quarter of the year, at 1,758, before settling at around 1,300 a quarter.

The reasons people gave are revealing. Clients could choose more than one, and the most common were general wellness (30.6 per cent), a change of perspective (27.7 per cent) and expanded consciousness (27 per cent). Anxiety (23.8 per cent) and depression (22 per cent) came next. In other words, most people did not describe their visit as treatment for anything.

The paper also found that about a third of clients (32.6 per cent) lived outside Oregon, and that most were women and white. The average dose was about 24.5 mg of psilocybin. The authors noted that the high cost of services may limit who can use them.

The first long-term study of clients

Dashboard numbers describe a programme. They do not show what happens to the people in it. For that, the most detailed evidence so far comes from a study led by Todd Korthuis at Oregon Health and Science University, published in JAMA Network Open in August 2026.

The team followed 346 adults who received services at 24 Oregon centres between November 2024 and March 2026. About 44 per cent had never used a psychedelic before. Participants completed questionnaires before their session and again at one week, one month and three months. About 90 per cent were still taking part at three months.

  • The share of participants with moderate to severe depression symptoms fell from 42.2 per cent at the start to 16.5 per cent at three months.
  • The share with moderate to severe anxiety symptoms fell from 45.1 per cent to 13.2 per cent.
  • Four participants, all first-time users, had behavioural reactions that needed medical attention.
  • Three participants reported new thoughts of death or suicide one week after their session, and that number had doubled by three months.

The researchers were careful about what this can and cannot show. There was no control group, participants chose to take part, and many started with fairly mild symptoms. One outside researcher also cautioned that the low rate of harm may partly reflect who decided to join. The study shows how a group of clients fared, not that psilocybin caused the changes.

Colorado is earlier in the process

Colorado voters approved Proposition 122, the Natural Medicine Health Act, in 2022. The state began accepting licence applications at the end of 2024, and The Center Origin in Denver became the first licensed healing centre on 31 March 2025.

Like Oregon, Colorado's centres serve adults 21 and older, with licensed facilitators present. By October 2026, the state's Natural Medicine Division listed more than 40 approved healing centre licences, most of them small "micro" centres.

What Colorado does not have yet is a large public dataset. A 2025 state law requires the health department to collect anonymous demographic and outcome data from facilitators and healing centres, so the first fuller picture should come from the state's annual reports. Until then, Oregon remains the main source of evidence.

What the two programmes are teaching

A few lessons stand out from the early data.

  • Structure matters. Both states built their programmes around preparation, a measured amount and a sober facilitator, the same elements researchers have long described as set and setting.
  • Most people are not seeking treatment. Wellness and curiosity outrank any condition in Oregon's figures.
  • Serious reactions are uncommon but real. In the Oregon Health and Science University study, all four reactions that needed medical attention happened to first-time users.
  • Real-world data is not trial data. For how the controlled trials compare, see the 2026 psilocybin depression trials.

Who should skip mushrooms

Do not use psilocybin if you are under 19, pregnant or breastfeeding, or have a personal or family history of psychosis or bipolar disorder. Do not combine it with lithium. Read psilocybin and medications and our safety guide first. Psilocybin is a controlled substance in Canada. This is not legal advice.

Measured amounts at home

One quiet lesson from Oregon is how much a known, measured amount helps. Regulated sessions record a dose of psilocybin itself, while capsule labels state the weight of dried mushroom, and potency differs between mushrooms, as our post on why potency varies explains. So the two are not directly comparable, but the principle carries over: know what you are taking.

If you prefer a stated amount over weighing, DÖSE MACRO Macrodose Psilocybin Capsules hold 450 mg of Golden Teacher fruiting body in each capsule. If you are new and would like to try more than one format first, the First Timer Magic Mushroom Kit puts dried Golden Teacher, chocolate, tea and a microdose bottle in one box. Whatever you choose, the same preparation Oregon's facilitators insist on applies at home: a calm setting, a clear head and someone you trust nearby.

Sources

What the research says

Research on psilocybin is still young, and most trials give a measured dose with professional support. Results don't mean any product is safe or effective for you.

This guide is general information, not medical or legal advice. If you have health questions, talk to a health professional.

Your next step

Ready for your first trip?

Not sure where to start? Our starter kits are picked for first-timers. Free shipping across Canada on orders over $130.